Kenvue (KVUE) Q2 2026: Miss Snaps a Four-Quarter Winning Streak
As seen on the 24/7 Wall St. homepage on August 6, 2026.
The Tylenol maker missed expectations on both lines, ending a four-quarter beat streak, with adjusted gross margin narrowing to 60.2% on inflation, tariffs and currency. No guidance is coming: the $48.7 billion Kimberly-Clark takeover is set to close in the fourth quarter, leaving foreign regulators as the last hurdle.
Continue ReadingShow less
Kenvue reported adjusted EPS of $0.31 for the second quarter of 2026, falling about 2.8% short of the $0.319 consensus estimate and ending four consecutive quarters of earnings beats. Revenue came in at $3.955 billion, just under the $3.969 billion analysts had expected. The dual miss marks a notable stumble for the Tylenol and Neutrogena parent after a run of solid outperformance stretching back through Q3 2024.
Margin pressure was at the center of the shortfall. Adjusted gross margin narrowed to 60.2%, weighed down by a combination of inflation, tariffs, and currency headwinds — a trio of costs that have been a recurring theme across consumer-goods companies this cycle. With those forces still in play, investors will be watching closely to see whether the margin squeeze deepens or stabilizes in the back half of the year.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
What makes the outlook especially hard to read is that Kenvue declined to issue guidance. The company's planned $48.7 billion acquisition of Kimberly-Clark is expected to close in the fourth quarter, and foreign regulatory approvals remain the last major obstacle. Until that deal clears, management appears unwilling to project a combined financial picture, leaving the near-term earnings trajectory unusually uncertain.
Mentioned: KVUE